Lilly Drops Zepbound Price, Compounders Sue FDA (again) OTP TWD 2.25.25
Send a textLilly releases higher dose Zepbound vials, reduces price for patients paying out of pocket. Meanwhile, the tirzepatide lawsuit heats up, with a potential ruing on preliminary injunction. Th...
25 Feb 202522min
Compound Tirzepatide Lawsuit Update / GLP-1 Heart Health w Dr Simin Lee / OTP Eps 102
Send a textOTP legal expert Lee Thomas joins to discuss the latest in the compound Tirzepatide lawsuit. Dr Simin Lee joins Dave to discuss obesity, GLP-1 medications and heart health!Decoding GLP-1: A...
21 Feb 20251h 23min
503A Compound Tirzepatide Deadline Is Here, What Next? // OTP TWD 2.18.25
Send a text📚 Book Relaunch: The book “Decoding GLP-1” is back on Amazon, now priced at $10, thanks to community advocacy.⏳ Compounding Update: The FDA has delayed enforcement on 503A pharmacies until...
18 Feb 202523min
Zepbound Weight Loss and Cancer Diagnosis // OTP Eps 101
Send a textOn the 101st episode of On The Pen Live, Dave discusses this week's news in GLP-1, we get weight loss maintenance tips from Korrie, and a Reddit recap from @FitFlavorFun ! For the intervie...
14 Feb 20251h 30min
Lilly Announces Next Gen Tirzepatide
Send a textBreaking Compound Tirzepatide NewsLilly announces next generation of GLP-1 / GIP medTrump advocates for cheaper "Fat Shot"HIMS faces industry scrutinyDecoding GLP-1: A Guide for Friends and...
11 Feb 202530min
GLP-1 Talk Show: An Emotional 100th On The Pen Live
Send a textIn the 100th episode of On The Pen Live, BJ Davis shares his inspiring 158 lb weight loss journey using Mounjaro, revealing how GLP-1 medications, exercise, and lifestyle changes transforme...
7 Feb 20251h 13min
Zepbound and Retatrutide News: Lilly Q4 Earnings Call Recap
Send a textDave Knapp breaks down what the Q4 Eli Lilly earnings call means for patients living with obesity.https://www.onthepen.com/post/lilly-s-earnings-call-could-reveal-big-changes-for-zepbound-r...
6 Feb 202533min
Novo Nordisk Q4 '24 Earnings Call: Obesity Medicine Implications
Send a textFrom high dose semaglutide to cagrisema launch dates, Dave Knapp discusses how the latest Novo Nordisk earnings call impacts patients.Decoding GLP-1: A Guide for Friends and Family of Those...
5 Feb 202536min
